Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast

Journal of Clinical Pathology
Ting LeiHong Bu

Abstract

The aim of this study was to analyse the clinicopathological features and prognosis of human epidermal growth factor receptor-2 (HER2)-positive metaplastic squamous cell carcinoma (MSCC). Fifty-eight patients with MSCC of the breast who were classified into 45 triple-negative and 13 HER2-positive subgroups diagnosed at the West China Hospital, Sichuan University, from 2004 to 2018, were enrolled. Clinicopathological features were collected and compared between HER2-positive MSCC, triple-negative MSCC, HER2-positive invasive breast carcinoma of no special type (NST) and triple-negative NST groups. In the prognostic survival analysis, HER2-positive MSCCs was compared with triple-negative MSCCs, HER2-positive NSTs and triple-negative NSTs. Compared with triple-negative MSCCs, more patients with Ki-67 low expression were in HER2-positive MSCCs (p<0.05). More patients with HER2-positive MSCC than patients with HER2-positive NST were postmenopausal (p<0.05). Compared among HER2-positive MSCCs, triple-negative MSCCs and triple-negative NSTs, patients of HER2-positive MSCCs with high Ki-67 expression were the least, and HER2-positive MSCCs had more strongly associated with postmenopausal disease status (p<0.05). In survival analyses, H...Continue Reading

References

Feb 10, 2010·Breast Cancer Research and Treatment·So-Youn JungJungsil Ro
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Feb 22, 2013·International Journal of Oncology·Hiroaki KatoKazuto Nishio
Mar 1, 2013·Histopathology·Matthias ChoschzickGuido Sauter
May 1, 2013·The American Journal of Surgical Pathology·Anupma NayakMichael Z Gilcrease
Feb 11, 2014·Advances in Anatomic Pathology·Uma Krishnamurti, Jan F Silverman
Mar 22, 2014·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Henning HankenMarco Blessmann
Nov 27, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Netanya I Pollock, Jennifer R Grandis
Feb 5, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Howard M SternMichael F Press
Nov 5, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yusuke InoueHaruhiko Sugimura
Mar 21, 2016·Cancer Treatment Reviews·Sherry X YangStanley Lipkowitz
Jun 18, 2016·OncoTargets and Therapy·Ximei ZhangPing Wang
Sep 26, 2016·The Breast : Official Journal of the European Society of Mastology·Fabinshy ThangarajahVerena Kirn
Feb 22, 2017·Pharmacology & Therapeutics·Nandini DeyBrian Leyland-Jones
Apr 23, 2017·Breast Cancer Research and Treatment·Siddhartha YadavDana Zakalik
Jul 25, 2017·The American Journal of Pathology·Felipe C GeyerJorge S Reis-Filho
Apr 10, 2018·The Breast : Official Journal of the European Society of Mastology·Santiago Escrivá-de-RomaníCristina Saura
May 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffMitchell Dowsett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Annals of Surgical Oncology
Haralabos Demetriades
The Lancet Oncology
Luc Y Dirix, Peter B Vermeulen
Clinical Advances in Hematology & Oncology : H&O
George W Sledge
© 2021 Meta ULC. All rights reserved